FIELD: medicine.
SUBSTANCE: proposed group of inventions relates to medicine. Disclosed are methods of delivering a protective ApoE isoform and nucleic acid coding same to the central nervous system of a mammal. Disclosed are an rAAV2 particle containing a vector comprising a nucleic acid encoding the protective isoform of ApoE ε2, and a pharmaceutical composition comprising said particle for the treatment of Alzheimer's disease.
EFFECT: disclosed group of inventions reduces risk of developing Alzheimer's disease and provides effective treatment thereof.
14 cl, 17 dwg, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND COMPOSITIONS FOR BRAIN DISEASES TREATMENT | 2014 |
|
RU2664471C2 |
| MODIFIED ADENO-ASSOCIATED VIRUS VECTOR COMPOSITIONS | 2013 |
|
RU2679843C2 |
| COMPOSITIONS, METHODS AND APPLICATIONS OF GENE TRANSFER FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES | 2017 |
|
RU2805606C2 |
| INTRATHECAL ADMINISTRATION OF VECTORS BASED ON ADENO ASSOCIATED VIRUSES FOR GENE THERAPY | 2016 |
|
RU2775138C2 |
| RNAi AGENT OPTION | 2018 |
|
RU2789647C2 |
| ADENO-ASSOCIATED VIRAL VECTORS FOR TREATMENT OF MYOCILIN (MYOC) GLAUCOMA | 2015 |
|
RU2746991C2 |
| THERAPEUTIC COMPOUNDS FOR TREATING HUNTINGTON'S DISEASE | 2015 |
|
RU2711147C2 |
| AVV VECTORS WITH IMPROVED Rep-CODING SEQUENCES USED IN INSECT CELL PRODUCTION SYSTEMS | 2007 |
|
RU2457252C2 |
| ADENO-ASSOCIATED VIRUS VECTORS FOR TREATING MYOCILIN (MYOC) GLAUCOMA | 2015 |
|
RU2718047C2 |
| ADENO-ASSOCIATED VIRAL VECTORS FOR TREATING MUCOLIPIDOSIS TYPE II | 2016 |
|
RU2742612C2 |
